Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 2
2003 1
2004 1
2005 4
2006 3
2007 2
2009 3
2010 1
2011 6
2012 8
2013 7
2014 10
2015 12
2016 6
2017 9
2018 6
2019 7
2020 15
2021 40
2022 20
2023 33
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayasamy Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S; CovidSurg Gynecological Cancer Collaborators. Fotopoulou C, et al. Am J Obstet Gynecol. 2022 Nov;227(5):735.e1-735.e25. doi: 10.1016/j.ajog.2022.06.052. Epub 2022 Jun 30. Am J Obstet Gynecol. 2022. PMID: 35779589 Free PMC article.
The Application of Hollow Fiber Cartridge in Biomedicine.
Hou Y, Mi K, Sun L, Zhou K, Wang L, Zhang L, Liu Z, Huang L. Hou Y, et al. Among authors: mi k. Pharmaceutics. 2022 Jul 18;14(7):1485. doi: 10.3390/pharmaceutics14071485. Pharmaceutics. 2022. PMID: 35890380 Free PMC article. Review.
Trends and challenges of multi-drug resistance in childhood tuberculosis.
Zhuang Z, Sun L, Song X, Zhu H, Li L, Zhou X, Mi K. Zhuang Z, et al. Among authors: mi k. Front Cell Infect Microbiol. 2023 Jun 2;13:1183590. doi: 10.3389/fcimb.2023.1183590. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37333849 Free PMC article. Review.
193 results